logo
Plus   Neg
Share
Email

Sika AG Q1 Sales Rise; Confirms FY19 Sales View - Quick Facts

Swiss specialty chemicals company Sika AG (SXYAY.PK,SKFOF.PK) reported Tuesday a successful start to the 2019 business year with first-quarter sales of 1.64 billion Swiss francs, an increase of 5.8%. Sales grew 7.1% in local currencies.

In the first quarter of 2019, sales in the Europe, Middle East, Africa or EMEA region increased by 8.2%, compared to last year's growth of 10.2%.

The Americas region recorded sales growth of 4.8% and sales in the Asia/Pacific region rose by 2.8%.

Looking ahead, for fiscal 2019, the company confirmed its sales target of at least 8 billion francs. With the consolidation of Parex tentatively taking place in the second quarter, sales is set to exceed 8 billion francs for the first time.

Sika expects sales to increase by 6-8% in 2019, in accordance with the Group's Strategic Targets 2020, and anticipates an over-proportional rise in profits.

The implementation of the Group's growth strategy will continue in 2019 with the opening of between seven and nine new factories, and the establishment of further growth platforms in the form of acquisitions.

Details of the new Strategy 2023 will be presented at the Sika Capital Markets Day on October 3, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Zoom Video Communications (ZM) gained 4% on extended session Tuesday after the video conferencing software company reported a first-quarter results that trumped Wall Street estimates and issued a outlook for the second and full year 2021 that is expected to beat current expectations. First-quarter... The National Retail Federation Chief Economist Jack Kleinhenz said it was too early to say how quickly or smoothly the U.S. economy would stage a recovery following the "sizable disruptions" due to the coronavirus pandemic. However, he noted that the reopening of businesses and the resumption of economic activity is a significant step forward. Following the recall of type 2 diabetes medication Metformin Hydrochloride Extended-Release (ER) by Apotex last week, the U.S. Food and Drug Administration or FDA has recommended more pharmaceutical companies, who are manufacturers of the drug formulation, to recall their products.
RELATED NEWS
Follow RTT